Amylyx Pharmaceuticals (AMLX) Return on Sales (2021 - 2025)

Amylyx Pharmaceuticals' Return on Sales history runs 5 years deep, the most recent figure standing at 1.36% for Q3 2025.

• On a quarterly basis, Return on Sales rose 310.0% year-over-year to 1.36% in Q3 2025; TTM through Sep 2025 was 1.36%, a 137.0% increase from a year earlier, with the FY2024 full-year figure at 0.03%, down 3.0% from the prior year.
• Return on Sales retreated to 1.36% in Q3 2025 per AMLX's latest filing, from 5.66% in the prior quarter.
• Across five years, Return on Sales topped out at 5.66% in Q2 2025 and bottomed at 1.94% in Q1 2025.
• The 5-year median for Return on Sales is 0.02% (2022), against an average of 0.01%.
• Biggest YoY gain for Return on Sales was 637 bps in 2025; the steepest drop was 193 bps in 2025.
• Year by year, Return on Sales stood at 0.81% in 2021, then surged by 98 bps to 0.02% in 2022, then jumped by 101 bps to 0.0% in 2023, then slumped by 161386 bps to 0.4% in 2024, then soared by 438 bps to 1.36% in 2025.
• Per Business Quant, the three latest AMLX Return on Sales figures stand at 1.36% (Q3 2025), 5.66% (Q2 2025), and 1.94% (Q1 2025).